Dr Hill was appointed as the Chief Medical & Strategy Officer at Oncimmune in early 2018. Having been exposed to Oncimmune’s early cancer detection technology on a number of occasions, he is impressed with the quality of it’s underpinning science, delighted with the simplicity of it’s implementation, and increasingly excited about it’s potential to impact Cancer outcomes globally through stage shift.
Dr Hill was previously the CMO for McLaren Applied Technologies, McLaren Groups’ advanced technology, innovation and design company. In this role Adam was responsible for directing and defining the Health business, and creating intelligent products and processes to improve health outcomes and reduce health inequality spanning from digital therapeutics to human performance.
A dual-qualified Clinician and Mechanical Engineer, Adam graduated from Imperial College London, the Royal Military Academy Sandhurst and the Royal College of Surgeons of England. In recent the recent past, he has successfully founded an applied health research centre, strategically advised global life science companies for the UK government and lead a multinational, publicly-listed Health IT brand.
In addition, Adam has contributed to over 100 publications, 12 academic awards and patents, and is a Visiting Professor in the Institute of Global Health Innovation at Imperial College London.